| Ms Beverly Burrowes-murray, MA,SLP | |
|
34 Grand Teton Dr, Bear, DE 19701-1790 | |
| (302) 832-1818 | |
| (302) 832-1818 |
| Full Name | Ms Beverly Burrowes-murray |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 34 Grand Teton Dr, Bear, Delaware |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023366929 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | 013877-1 (New York) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Ms Beverly Burrowes-murray, MA,SLP 34 Grand Teton Dr, Bear, DE 19701-1790 Ph: (302) 832-1818 | Ms Beverly Burrowes-murray, MA,SLP 34 Grand Teton Dr, Bear, DE 19701-1790 Ph: (302) 832-1818 |
News Archive
According to a new report from four major national cancer tracking groups there has been a steady decline in cancer death rates for men, women and children from 2004 to 2008. The declines in death and new cases of cancer reflect progress against the disease in terms of prevention, diagnosis and treatment, but experts say rising obesity may present a new challenge in the fight against cancer.
Arena Pharmaceuticals, Inc. and Eisai Inc. announced today that the US Food and Drug Administration (FDA) has notified the company of the confirmed scheduling of an Endocrinologic and Metabolic Drugs Advisory Committee meeting on September 16, 2010, for the review of the lorcaserin New Drug Application (NDA). Lorcaserin, which Arena discovered and has developed for weight management, is intended for obese patients as well as overweight patients who have at least one weight-related co-morbid condition.
Instituting a partial smoking ban at a homeless shelter can lead to a reduction in expired carbon monoxide levels, an indicator of exposure to cigarette smoke, and may have positive effects on shelter residents' health, according to new research. The University of Texas Health Science Center at Houston released the study results last week in the journal Addictive Behaviors.
Genta Incorporated today announced preliminary results from AGENDA, the Company's Phase 3 trial of Genasense® (oblimersen sodium) Injection in patients with advanced melanoma. AGENDA is a randomized, double-blind, placebo-controlled trial of dacarbazine (DTIC) administered with or without Genasense® in patients who have not previously received chemotherapy.
› Verified 1 days ago
Christine Schenk, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 925 Bear Corbitt Rd, Bear, DE 19701 Phone: 302-454-2400 Fax: 302-454-5442 | |
Danieska Giron-querales, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2 Violet Ct, Bear, DE 19701 Phone: 302-464-0214 | |
Wendy Coral, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 925 Bear Corbitt Rd, Bear, DE 19701 Phone: 302-454-2400 Fax: 302-454-5440 | |
Laurence Devlin, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 925 Bear Corbitt Rd, Bear, DE 19701 Phone: 302-454-2400 Fax: 302-454-5442 | |
Miss Julia Elizabeth Mariotti, MS, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 925 Bear Corbitt Rd, Bear, DE 19701 Phone: 302-454-2400 | |
Emma L Richardson, M.A., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 925 Bear Corbitt Rd, Bear, DE 19701 Phone: 610-781-1481 |